News
Get access to our breaking news, and company information
Press Releases
Pillar Biosciences to Present at NYBIO | NYSE Life Science Company Showcase on December 14th
Natick, MA – December 7, 2023 – Pillar Biosciences is pleased to announce that Randy Pritchard, Chief Executive Officer, and Vincent Ricci, Chief Financial Officer,
Pillar Biosciences to Present New Scientific Data at Association for Molecular Pathology Annual Meeting
NATICK, Mass. – November 8, 2023 – (PR NEWSWIRE) – Pillar Biosciences, Inc., the leader in Decision Medicine™, today announced the company and scientific collaborators
Beckman Coulter Life Sciences and Pillar Biosciences Announce NGS Application Development Pipeline for the Biomek NGeniuS System
Assays Focus on Accelerating Cancer Research INDIANAPOLIS – November 6, 2023 – Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, continues
Pillar Biosciences Launches oncoReveal Core LBx, an NGS Kit to Enable Localized Liquid Biopsy-Based Tumor Profiling
Research Use Only (RUO) NGS Kit will provide a simple, automatable, industry-leading liquid biopsy workflow NATICK, Mass. – September 19, 2023 – (PR NEWSWIRE) –
Illumina and Pillar Biosciences Partner to Improve Access to Personalized Cancer Treatment Options
SAN DIEGO, JULY 25, 2023 /PRNewswire/ — Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and Pillar Biosciences Inc., the
Pillar Biosciences and KeyGene Enter into Licensing Agreement
NATICK, Mass. and WAGENINGEN, Netherlands, April 13, 2023 /PRNewswire/ — Pillar Biosciences, Inc., the leader in Decision Medicine™, which develops and distributes next-generation sequencing (NGS) tests to localize testing and